Single Dose MPCs Injection + Single Dose MPCs Injection

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Degenerative Disc Disease

Conditions

Degenerative Disc Disease

Trial Timeline

Aug 1, 2011 → Jul 1, 2015

About Single Dose MPCs Injection + Single Dose MPCs Injection

Single Dose MPCs Injection + Single Dose MPCs Injection is a phase 2 stage product being developed by Mesoblast for Degenerative Disc Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01290367. Target conditions include Degenerative Disc Disease.

What happened to similar drugs?

1 of 6 similar drugs in Degenerative Disc Disease were approved

Approved (1) Terminated (1) Active (4)
PimavanserinAcadia PharmaceuticalsApproved
LatozinemabAlectorPhase 3
🔄Pimavanserin + PlaceboAcadia PharmaceuticalsPhase 3
🔄PimavanserinAcadia PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01290367Phase 2Completed